ProCE Banner Activity

Accelerating the Pace Toward the End of the HIV Epidemic

Video

Hear insights from 4 faculty experts as they engage in a lively discussion on reaching the undiagnosed, care pathways after HIV testing, and treatment initiation and persistence.

Released: September 01, 2022

Expiration: August 31, 2023

No longer available for credit.

Share

Faculty

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Linda-Gail Bekker

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD

Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa

Nagalingeswaran Kumarasamy

Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD

Chief & Director
VHS-Infectious Diseases Medical Centre
Director
Chennai Antiviral Research and Treatment (CART) Clinical Research Site
Voluntary Health Services
Chennai, India

Chloe Orkin

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Gilead Sciences, Inc.

Target Audience

This program is intended for physicians, pharmacists, and other healthcare professionals who provide care for patients with HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply strategies to improve rates of HIV screening, especially in settings with disproportionate rates of underdiagnosis, and to minimize loss to follow-up during linkage to treatment or prevention services
  • Integrate practical interventions to ensure prompt initiation of guideline-recommended ART regimens to benefit both individual and public health
  • Implement approaches to ensure long-term persistence on ART, including attention to patient satisfaction with their regimens and the potential impact of socioeconomic barriers

Program Director Disclosure

Program Director

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS: consultant/advisor/speaker: GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, ViiV.

Faculty Disclosure

Primary Author

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD

Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa

Linda Gail-Bekker MBChB, DTM&H, DCH, FCP(SA), PhD: consultant/advisor/speaker: Cepheid, CIPLA, Gilead, Janssen, Johnson & Johnson, Merck, Novartis, ViiV.

Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD

Chief & Director
VHS-Infectious Diseases Medical Centre
Director
Chennai Antiviral Research and Treatment (CART) Clinical Research Site
Voluntary Health Services
Chennai, India

Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD, has no relevant financial relationships to disclose.

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD: consultant/advisor/speaker: Gilead, Janssen, MSD, ViiV; researcher: Gilead, Janssen, MSD, ViiV.

Staff Disclosure

Staff

Sarah Anderson, PharmD

Scientific Director

Sarah Anderson, PharmD: previous stock ownership: Merck.

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer Blanchette, PhD, has no relevant financial relationships to disclose.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant financial relationships to disclose.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant financial relationships to disclose.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no relevant financial relationships to disclose.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant financial relationships to disclose.

Additional Information

Program Medium

This program has been made available online.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

 

Goal


The goal of this activity is to improve learners’ competence in deploying strategies to address key gaps in HIV diagnosis and treatment and contribute to progress toward ending the HIV epidemic.